Skip to main content

Sustained Remission From Weeks 16 to 52 and Weeks 24 to 52 in Patients Treated With Sarilumab: Post-hoc Analysis of SAPHYR Trial in Patients With Polymyalgia Rheumatica

  • Sponsored by Sanofi

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×